3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King)

The article highlights three dividend-focused long-term picks: AbbVie (Dividend King with 53 straight years of dividend hikes) and an announced $10.9B acquisition of Apogee Therapeutics to expand its immunology pipeline, Enbridge (31 straight years of dividend growth; ~5.6% yield) targeting ~5% CAGR in distributable cash flow/earnings/EBITDA, and Realty Income (31-year dividend growth; 674 consecutive months paid) with a diversified property portfolio. Overall, the message is that these companies’ dividend durability and growth drivers support steady total returns despite product-cycle risk at AbbVie (Humira patent expiration addressed via Skyrizi and Rinvoq).

Analysis

This reads more like a factor advertisement than a fresh fundamental catalyst, so the market impact is likely to be in positioning rather than earnings power. The common denominator across all three names is duration: they work best when investors are paying up for cash yield and paying less attention to real-rate risk. That makes them vulnerable if the 10-year Treasury stays sticky or credit spreads widen, even if company-level fundamentals remain intact.

ABBV is the cleanest idiosyncratic story because it combines cash-flow visibility with M&A optionality; that supports a premium versus slower-growth large-cap pharma. The second-order winner from an acquisition mindset is APGE, which can gain scarcity value from being perceived as a takeout asset, while weaker pipeline-heavy pharma names can lose relative appeal if capital discipline is rewarded. The main falsifier is any sign that post-Humira growth is slowing faster than expected or that leverage rises enough to constrain future deal-making.

ENB and O are more macro trades than single-name stories. ENB benefits if data-center and LNG buildout translates into incremental contracted volumes, but the bigger trade is that pipeline cash flows can outperform rate-sensitive utilities and REITs on a relative basis if the market rotates toward industrial growth over bond proxies. O is the most exposed to multiple compression: the dividend is sturdy, but the equity can still lag badly if financing costs stay elevated or cap rates fail to widen enough for accretive expansion.

Key Decisions for Investors

• Long ABBV on weakness, 3-6 month horizon; favor it as a quality-cash-flow pharma compounder with M&A optionality. Falsify if guidance implies growth deceleration or if the market stops rewarding premium balance-sheet usage.
• Relative-value: long ABBV / short XBI or a weaker large-cap pharma basket over 1-3 months; this isolates the market’s preference for durable cash flow versus low-quality biotech duration. Risk is a sharp biotech beta rebound or a sector-wide risk-on squeeze.
• Pair trade: long ENB / short XLU for a 3-6 month factor rotation view; ENB should outperform if infrastructure-linked gas demand stays firm while utility multiples remain rate-sensitive. Stop if long-end yields fall hard and utilities re-rate faster than midstream.
• Avoid chasing O after the article-driven bid; only buy on a pullback or after a 25-50 bp decline in 10-year yields. The risk/reward is poor if rates stay high because the dividend can be right and the stock still underperform.
• Watch APGE as a merger-arb alert rather than a core recommendation; only engage if a measurable spread opens and the implied annualized return compensates for deal/regulatory risk.